21.24 USD
+0.17 (+0.81%)
At close: Feb 10, 2026
21.24 USD
0 (0%)
After Hours: 2/10/2026, 8:00:00 PM
Taking everything into account, PCRX scores 6 out of 10 in our fundamental rating. PCRX was compared to 191 industry peers in the Pharmaceuticals industry. While PCRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. These ratings would make PCRX suitable for value investing!
1. Profitability
1.1 Basic Checks
- PCRX had positive earnings in the past year.
- In the past year PCRX had a positive cash flow from operations.
- PCRX had positive earnings in 4 of the past 5 years.
- Each year in the past 5 years PCRX had a positive operating cash flow.
1.2 Ratios
- PCRX has a Return On Assets of 1.65%. This is amongst the best in the industry. PCRX outperforms 81.15% of its industry peers.
- PCRX's Return On Equity of 2.95% is amongst the best of the industry. PCRX outperforms 82.20% of its industry peers.
- PCRX has a better Return On Invested Capital (3.63%) than 81.68% of its industry peers.
- PCRX had an Average Return On Invested Capital over the past 3 years of 4.30%. This is significantly below the industry average of 12.66%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- With a decent Profit Margin value of 2.99%, PCRX is doing good in the industry, outperforming 79.58% of the companies in the same industry.
- With an excellent Operating Margin value of 8.88%, PCRX belongs to the best of the industry, outperforming 80.63% of the companies in the same industry.
- PCRX's Operating Margin has improved in the last couple of years.
- PCRX has a Gross Margin of 79.17%. This is amongst the best in the industry. PCRX outperforms 84.29% of its industry peers.
- In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, PCRX has less shares outstanding
- PCRX has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for PCRX is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 1.88 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- With a Altman-Z score value of 1.88, PCRX perfoms like the industry average, outperforming 59.69% of the companies in the same industry.
- The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
- PCRX's Debt to FCF ratio of 3.03 is amongst the best of the industry. PCRX outperforms 91.10% of its industry peers.
- PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
- The Debt to Equity ratio of PCRX (0.52) is worse than 62.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.88 |
ROIC/WACC0.46
WACC7.95%
2.3 Liquidity
- PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- PCRX's Current ratio of 5.26 is fine compared to the rest of the industry. PCRX outperforms 64.40% of its industry peers.
- A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
- With a Quick ratio value of 3.78, PCRX perfoms like the industry average, outperforming 59.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- The earnings per share for PCRX have decreased by -6.90% in the last year.
- The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
- Looking at the last year, PCRX shows a very negative growth in Revenue. The Revenue has decreased by -16.85% in the last year.
- The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- Based on estimates for the next years, PCRX will show a small growth in Earnings Per Share. The EPS will grow by 7.01% on average per year.
- Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.38% on average per year.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 7.15 indicates a rather cheap valuation of PCRX.
- PCRX's Price/Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 93.72% of the companies in the same industry.
- PCRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.03.
- Based on the Price/Forward Earnings ratio of 6.11, the valuation of PCRX can be described as very cheap.
- Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 94.24% of the companies in the same industry.
- PCRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.97, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.15 | ||
| Fwd PE | 6.11 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaper than 96.86% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 95.81% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.36 | ||
| EV/EBITDA | 6.12 |
4.3 Compensation for Growth
- The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.51
EPS Next 2Y4.05%
EPS Next 3Y6.92%
5. Dividend
5.1 Amount
- No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
21.24
+0.17 (+0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners114.44%
Inst Owner Change-1.64%
Ins Owners0.79%
Ins Owner Change-6.78%
Market Cap913.74M
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (42.7%)
Short Float %16.85%
Short Ratio7.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)0%
PT rev (3m)-20.55%
EPS NQ rev (1m)-0.63%
EPS NQ rev (3m)2.78%
EPS NY rev (1m)-0.31%
EPS NY rev (3m)2.87%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)-1.65%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.15 | ||
| Fwd PE | 6.11 | ||
| P/S | 1.27 | ||
| P/FCF | 7.36 | ||
| P/OCF | 6.46 | ||
| P/B | 1.26 | ||
| P/tB | 2.82 | ||
| EV/EBITDA | 6.12 |
EPS(TTM)2.97
EY13.98%
EPS(NY)3.48
Fwd EY16.36%
FCF(TTM)2.89
FCFY13.59%
OCF(TTM)3.29
OCFY15.48%
SpS16.66
BVpS16.9
TBVpS7.54
PEG (NY)N/A
PEG (5Y)0.51
Graham Number33.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 1.88 |
F-Score7
WACC7.95%
ROIC/WACC0.46
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.3%
EBIT Next 3Y6.32%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.15 and the Price/Book (PB) ratio is 1.26.